MT Newswires
Zai Lab Says New Drug Application for Schizophrenia Treatment Cobenfy Approved by China's National Medical Products Administration
📈
AI Sentiment
Highly Positive
8/10
- Home
- ZLAB
ZLAB
Zai Lab Limited
as of 12-26-2025 3:59pm EST
$18.34
$0.24
-1.29%
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
| Founded: | 2013 | Country: | China |
| Employees: | N/A | City: | SHANGHAI |
| Market Cap: | 2.0B | IPO Year: | 2017 |
| Target Price: | $57.22 | AVG Volume (30 days): | 937.7K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.82 - $44.34 | Next Earning Date: | 11-06-2025 |
| Revenue: | $441,629,000 | Revenue Growth: | 24.14% |
| Revenue Growth (this year): | 26.16% | Revenue Growth (next year): | 30.62% |
AI-Powered ZLAB Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 72.55%
72.55%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Zai Lab Limited (ZLAB)
Edmondson Frazor Titus III
Sell
Chief Legal Officer
ZLAB Dec 16, 2025
Avg Cost/Share
$17.14
Shares
8,651
Total Value
$148,278.14
Owned After
19,086
SEC Form 4
Edmondson Frazor Titus III
Sell
Chief Legal Officer
ZLAB Nov 21, 2025
Avg Cost/Share
$19.78
Shares
14,328
Total Value
$283,407.84
Owned After
19,086
SEC Form 4
Chen Yajing
Sell
Chief Financial Officer
ZLAB Nov 3, 2025
Avg Cost/Share
$26.83
Shares
240
Total Value
$6,439.44
Owned After
17,444
SEC Form 4
Chen Yajing
Sell
Chief Financial Officer
ZLAB Oct 2, 2025
Avg Cost/Share
$34.25
Shares
456
Total Value
$15,616.63
Owned After
17,444
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Edmondson Frazor Titus III | ZLAB | Chief Legal Officer | Dec 16, 2025 | Sell | $17.14 | 8,651 | $148,278.14 | 19,086 | |
| Edmondson Frazor Titus III | ZLAB | Chief Legal Officer | Nov 21, 2025 | Sell | $19.78 | 14,328 | $283,407.84 | 19,086 | |
| Chen Yajing | ZLAB | Chief Financial Officer | Nov 3, 2025 | Sell | $26.83 | 240 | $6,439.44 | 17,444 | |
| Chen Yajing | ZLAB | Chief Financial Officer | Oct 2, 2025 | Sell | $34.25 | 456 | $15,616.63 | 17,444 |
Latest Zai Lab Limited News
ZLAB Breaking Stock News: Dive into ZLAB Ticker-Specific Updates for Smart Investing
Business Wire
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia
📈
AI Sentiment
Highly Positive
10/10
Compare ZLAB vs Leading Stocks
See how ZLAB stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ZLAB Zai Lab Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.